Portal de Periódicos da CAPES

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

2021; Elsevier BV; Volume: 398; Issue: 10298 Linguagem: Inglês

10.1016/s0140-6736(21)01642-1

1474-547X

Madhumita Shrotri, Annalan M D Navaratnam, Vincent Nguyen, Thomas Byrne, Cyril Geismar, Ellen Fragaszy, Sarah Beale, Wing Lam Erica Fong, Parth Patel, Jana Kovar, Andrew Hayward, Robert W Aldridge,

Radiopharmaceutical Chemistry and Applications

Vaccines based on the spike glycoprotein of SARS-CoV-2 are being rolled out globally to control transmission and limit morbidity and mortality due to COVID-19. Current evidence indicates strong immunogenicity and high short-term efficacy for BNT162b2 (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca).1–3 Both vaccines are delivered through a prime-boost strategy, and many countries, including the UK, have used dose intervals longer than 3–4 weeks, expecting to maximise first-dose coverage and immunogenicity.